• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
      • Corporate image
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
        • ENERGI-F703 ENERGI-F701 ENERGI-F711
      • metabolic diseases
        • ENERGI-F702
      • Anti-inflammation
        • ENERGI-F704 ENERGI-F708
      • Diseases related to deficient mitochondrion
        • ENERGI-F705 ENERGI-F707
      • Others
        • ENERGI-F706 ENERGI-F709 ENERGI-F710
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
    • Company
    • Financial information
      • Monthly revenue information
      • Financial report
    • Shareholders
      • Shareholders' Meeting
      • Dividend policy and dividend distribution
      • Public specification
      • Stock price information
      • Corporate briefing
      • Important information
      • Investment service window
      • Links
    • Corporate Governance
      • Member of the board
      • Functional committee
      • Various management measures
      • Internal audit
      • Head of Corporate Governance
    • Corporate social responsibility
      • Performance of corporate responsibility
      • Corporate Integrity Zone
      • Stakeholder
  • Careers

About us

Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
MORE

Information

  • 2024-10 EB Announces Exclusive Licensing Agreement with PBI Portugal Unipessoal Lda., a wholly owned subsidiary of the German group Pharma Bavaria International
  • 2024-10 EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's Disease.
  • 2024-10 EB's proprietary 'METHOD FOR TREATING EPIDERMO-LYSIS BULLOSA' has been granted patent approval by the Intellectual Property Office
  • 2024-09 Energenesis's Novel Diabetic Foot Ulcer Gel Wins Excellence Award in Innovation Technology at 2024 Taipei Biotech Awards
  • 2024-09 Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry
MORE

New medicine development platform

ENERGI-F703

ENERGI-F701

  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 20204 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice